Business Combinations, Divestitures (Details) - USD ($) $ in Millions			12 Months Ended
		Feb. 23, 2021	Jun. 30, 2021		Jun. 30, 2020		Jun. 30, 2019
Business Acquisition [Line Items]
Goodwill, Acquired During Period			$ 56	[1]	$ 264	[2]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	[3]		182		$ (1)		$ 0
Blow-Fill-Seal Business, Woodstock
Business Acquisition [Line Items]
Proceeds from Divestiture of Businesses and Interests in Affiliates			300
Business Combination, Acquired Receivables, Gross Contractual Amount			50
Business Combination, Acquired Receivable, Fair Value	[4]		47
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			50
Disposal Group, Including Discontinued Operation, Assets			149
Goodwill, Acquired During Period			54
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal			182
Business Combination, Loan Discount			3
Business Acquisition, Transaction Costs			8
Business Combination, Working Capital Adjustments			6
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			2
Proceeds From Divestiture Of Businesses, Net Cash Proceeds			287
Business Combination, Contingent Consideration, Asset	[5]		0
Business Combination, Consideration Transferred, Other	[6]		16
Cash and Noncash Divestiture, Amount of Consideration Received			331
Accrued Liabilities, Fair Value Disclosure			$ 3
Delphi Genetics SA
Business Acquisition [Line Items]
Goodwill, Acquired During Period		$ 45
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		$ 5

[1] The addition in the Biologics segment relates to the Skeletal and Delphi acquisitions. The addition in the Oral and Specialty Delivery segment relates to the Acorda transaction. For further details, see Note 3, Business Combinations and Divestitures.

[2] The increase in fiscal 2020 primarily relates to the MaSTherCell acquisition. See Note 3, Business Combinations and Divestitures.

[3] Gain on sale of subsidiary for the fiscal year ended June 30, 2021 is affiliated with the sale of the Blow-Fill-Seal Business. Loss on sale of subsidiary for the fiscal year ended June 30, 2020 is affiliated with the disposal of the Australia facility.

[4] The note receivable, which provides for interest at a rate of 5.0% paid in kind, had an estimated fair value of $47 million at June 30, 2021, which is the $50 million aggregate principal amount less a $3 million discount determined using a discounted cash flow model with the market interest rate as a significant input.

[5] The Company determined that the estimated fair value of the contingent consideration from the sale of the Blow-Fill-Seal Business at June 30, 2021 was zero, and therefore no contingent consideration was recorded at divestiture. If any contingent consideration is subsequently received, it will be recorded in the period in which it is received. The Company has elected an accounting policy to recognize increases in the carrying amount of the contingent consideration asset using the gain contingency guidance in ASC 450, Contingencies.

[6] Other includes $8 million of transaction expenses, a working capital adjustment of $6 million, and $2 million assumption of liabilities resulting in net cash proceed of $287 million for the fiscal year ended June 30, 2021, with an additional $3 million accrued at June 30, 2021 as a post-closing purchase price adjustment. The final post-closing purchase price adjustment was paid by the Company in August 2021.